Background Whether the two drug-eluting stents approved by the US Food and Drug
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …

Aims To evaluate the effect of drug-eluting vs. bare metal stents for the treatment of coronary
artery disease on overall, cardiac, and non-cardiac mortalities. Methods and results We …

Objectives: Novel stents loaded with an integrin-binding cyclic Arg-Gly-Asp peptide (cRGD)
were analyzed for their potential to limit coronary neointima formation and to accelerate …

BACKGROUND: Cardiac surgery is the standard treatment for unprotected left main disease
(ULM). Drug-eluting stent (DES) implantation has been recently reported in patients with …

BACKGROUND: Treatment of coronary artery disease (CAD) is evolving with better
medications, improvements in percutaneous coronary intervention (PCI), and enhanced …

Iwould like to thank the Society of Thoracic Surgery and, in particular, Dr Sydney Levitsky,
the President, for the honor and privilege of presenting this Sixth Annual Thomas B …

Coronary stenting is the most common form of interventional treatment for symptomatic
coronary artery disease. In-stent restenosis following bare metal stent (BMS) placement is …

Objectives: This study investigated the risk of stent thrombosis associated with the use of
paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS). Background: Clinical …

Objective To appraise multiple systematic reviews on the same clinical topic, focusing on
predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores. Design …

Local drug presentation made possible by drug-eluting depots has demonstrated benefits in
a vast array of diseases, including in cancer, microbial infection and in wound healing …